On October 2, BEONE MEDICINES fell 6.3% in regular trading, trading at 209.6 HKD/share, with turnover of approximately 105 million HKD.

Within the Biotechnology sector where BEONE MEDICINES belongs, the overall sector came under broad selling pressure. Among individual stocks, INNOVENT BIO down 5.1%, AKESO down 2.67%, SKB BIO down 4.52%, 3SBIO down 5.43%, HENLIUS down 3.32%.

BEONE MEDICINES is a global oncology company focused on developing novel therapies for cancer patients worldwide. Its product portfolio spans hematology and solid tumors, with key marketed products including Brukinsa, Tevimbra, and Pamiparib, alongside a deep pipeline of next-generation candidates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)